However, the combination of low MGMT expression (Fig. 1B) and elevated NUPR1 expression (Fig. 6B) may be a suitable biomarker to predict responsiveness to TFP in patients with GBM, and ongoing studies will investigate this. The gene discussed is NUPR1; the disease is glioblastoma.